105 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
11
Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).
University of Bergen
2
Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors.
Georgia State University
34
Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.
University of Sherbrooke
16
Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.
Second University of Naples
24
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.
Shandong University
2
Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.
Shandong University
2
Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.
Tokyo Medical and Dental University
20
Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.
National Health Research Institutes
16
Discovery of novel N-aryl piperazine CXCR4 antagonists.
Emory Institute For Drug Development
2
Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.
Emory University
16
Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).
Uit The Arctic University of Norway
27
Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.
Kyoto University
11
Toward fluorescent probes for G-protein-coupled receptors (GPCRs).
Shandong University
13
Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.
Montana State University
22
Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
Kyoto University
33
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
Universite£
1
Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.
TBA
16
Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4).
University of Troms£
4
Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.
Universitat Ramon Llull
8
Structure-activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres.
Kyoto University
15
Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Ono Pharmaceutical
10
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Anormed
20
Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Kyoto University
2
Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.
Pharmadesign
20
Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.
Technische Universit£T M£Nchen
36
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Ono Pharmaceutical
4
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.
Emory University
27
Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Genzyme
2
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
National Institute of Infectious Diseases
19
Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.
Genzyme
3
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
Tokyo Medical and Dental University
1
Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.
Glaxosmithkline
3
Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.
Glaxosmithkline
19
Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
Genzyme
3
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.
Glaxosmithkline
12
Identification of a new class of small molecule C5a receptor antagonists.
Wyeth Research
1
64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.
National Institute of Biomedical Imaging and Bioengineering
23
Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.
Novartis Institutes For Biomedical Research
26
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Roche Palo Alto
9
Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Kyoto University
2
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.
Université
4
Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.
University of Copenhagen
18
1,5-Disubstituted 1,2,3-triazoles: Molecular scaffolds for medicinal chemistry and biomolecular mimetics.
Indira Gandhi National Tribal University
22
Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.
Istituto Nazionale per lo Studio e la Cura dei Tumori-IRCCS-Fondazione "G. Pascale"
6
Grafting a chromophore on AMD070 analogues for CXCR4 bioimaging: Chemical synthesis and in vitro assessment of the inhibition properties of the CXCR4 receptor.
University of Brest
7
Recent advances in peptoids as promising antimicrobial agents to target diverse microbial species.
Wuhan Institute of Technology
5
Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.
University of Naples "Federico II"
22
Development and therapeutic perspectives of CXCR4 antagonists for disease therapy.
Sichuan University
1
Discovery of novel CXCR4 inhibitors for the treatment of inflammation by virtual screening and biological evaluation.
Anhui Medical University
3
Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4.
Hangzhou Normal University
32
Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability.
Ulm University Medical Center
34
Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities.
Kyoto University
21
Recent advances in small molecule based cancer immunotherapy.
Southern Medical University
29
Structural Analysis of Chemokine Receptor-Ligand Interactions.
Vrije Universiteit Amsterdam
10
HIV-1 gp120-CXCR4 recognition probed with synthetic nanomolar affinity D-peptides containing fragments of gp120 V3 loop.
Tsinghua University
19
Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists.
Tsinghua University
3
A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist.
Tsinghua University
32
Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.
Kyoto University
8
Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.
Kyoto University
15
Amino-Heterocycle Tetrahydroisoquinoline CXCR4 Antagonists with Improved ADME Profiles via Late-Stage Buchwald Couplings.
Emory University
48
Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists.
University of Michigan
16
Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.
Soochow University
7
Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry.
Virginia Commonwealth University
5
Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets.
University of Florida
41
Structural optimization of aminopyrimidine-based CXCR4 antagonists.
Soochow University
95
Discovery of the Potent, Selective, Orally Available CXCR7 Antagonist ACT-1004-1239.
Idorsia Pharmaceuticals
5
Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer.
Virginia Commonwealth University
6
Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
Kyoto University
19
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.
Merck Research Laboratories
16
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.
Merck Research Laboratories
4
Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.
Pfizer
2
Discovery of small molecule antagonists of chemokine receptor CXCR6 that arrest tumor growth in SK-HEP-1 mouse xenografts as a model of hepatocellular carcinoma.
Sanford Burnham Prebys Medical Discovery Institute
24
Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4.
Upstate Medical University
9
High affinity CXCR4 inhibitors generated by linking low affinity peptides.
University of California San Diego
2
Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.
Emory University
34
Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.
Griffin Discoveries
7
Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands.
Tokyo Medical and Dental University (Tmdu)
29
The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors.
Kyowa Kirin
37
Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
Glaxosmithkline
10
HIV-1 X4 activities of polycationic "viologen" based dendrimers by interaction with the chemokine receptor CXCR4: study of structure-activity relationship.
University of Osnabr£Ck
25
The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.
Central South University
24
Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.
Soochow University
34
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties.
Emory University
2
Insight into structural requirements for selective and/or dual CXCR3 and CXCR4 allosteric modulators.
University of Ljubljana
16
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-Chains.
Emory University
28
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.
Emory University
20
An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.
University of Calabria
49
Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties.
Emory University
17
Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.
Pfizer
60
Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).
Kyoto University
68
Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.
Gsk Pharmaceuticals R & D
19
Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.
University of Campania
25
Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond.
National Health Research Institutes
6
Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)-Ligand Interactions on Living Cancer Cells.
University of Naples Federico II
44
TETRAHYDROQUINOLINE (THQ) COUMPOUNDS
Centre National de la Recherche Scientifique
8
1,3,5-triazine derivative and method of using same
Chia Tai Tianqing Pharmaceutical Group